LENZ Therapeutics provided Phase 3 timing and formulation guidance for LNZ100 and LNZ101. LNZ100 is a 1.75% Aceclidine based eye drop while LNZ101 is a 1.75% Aceclidine based eye drop with Brimonidine. Both use LENZ's proprietary preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.
LENZ Therapeutics to attend AAO 2021
LENZ Therapeutics to present at Eyecelerator @ AAO 2021
LENZ Therapeutics to attend Academy Boston 2021
LENZ Therapeutics CEO Eef Schimmelpennink speaks with RApport about seeking out a new challenge and helping 120 million Americans ditch their reading glasses.